Antileishmanial Effects of Synthetic EhPIb Analogs Derived from the Entamoeba histolytica Lipopeptidephosphoglycan

With an estimated number of new cases annually of approximately 1.4 million, leishmaniasis belongs to the most important parasitic diseases in the world. Nevertheless, existing drugs against leishmaniasis in general have several drawbacks that urgently necessitate new drug development. A glycolipid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Fehling, Helena, Choy, Siew Ling, Ting, Frederic, Landschulze, Dirk, Bernin, Hannah, Lender, Sarah Corinna, Mühlenpfordt, Melina, Bifeld, Eugenia, Eick, Julia, Marggraff, Claudia, Kottmayr, Nadine, Groneberg, Marie, Hoenow, Stefan, Sellau, Julie, Clos, Joachim, Meier, Chris, Lotter, Hannelore
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2020
Schlagworte:
Experimental Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318009/
https://ncbi.nlm.nih.gov/pubmed/32393489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00161-20
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge